Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines.

Caminero JA, García-Basteiro AL, Rendon A, Piubello A, Pontali E, Migliori GB.

Eur Respir J. 2019 Oct 10;54(4). pii: 1901272. doi: 10.1183/13993003.01272-2019. Print 2019 Oct. No abstract available.

PMID:
31601719
2.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.

Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Loidi JC, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios Jefe J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Salinas NE, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Rosso RG, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Robles EM, Matteelli A, Mazza-Stalder J, Moschos C, Munoz-Torrico M, Hamdan HM, Nakčerienė B, Nicod L, Marcos MN, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB.

Eur Respir J. 2019 Oct 10. pii: 1901522. doi: 10.1183/13993003.01522-2019. [Epub ahead of print]

PMID:
31601711
3.

Multidrug-resistant tuberculosis.

Caminero JA, García-Basteiro AL, Rendon A.

Lancet. 2019 Jul 27;394(10195):298. doi: 10.1016/S0140-6736(19)30696-8. No abstract available.

PMID:
31354137
4.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.

Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring.

Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3.

5.

Curving Tuberculosis: Current Trends and Future Needs.

Rojano B, Caminero JA, Hayek M.

Ann Glob Health. 2019 Jan 22;85(1). pii: 5. doi: 10.5334/aogh.2415. Review.

6.

Management of Multidrug-Resistant Tuberculosis.

Daley CL, Caminero JA.

Semin Respir Crit Care Med. 2018 Jun;39(3):310-324. doi: 10.1055/s-0038-1661383. Epub 2018 Aug 2. Review.

PMID:
30071546
7.

The Historical Need for a National Tuberculosis Program for Spain.

Caylà JA, Caminero JA.

Arch Bronconeumol. 2018 Dec;54(12):603-604. doi: 10.1016/j.arbres.2018.06.013. Epub 2018 Jul 23. English, Spanish. No abstract available.

8.

The economic burden of multidrug-resistant tuberculosis.

Caminero JA, Scardigli A.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):831-832. doi: 10.5588/ijtld.18.0408. No abstract available.

PMID:
29991388
9.

ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update.

Migliori GB, Sotgiu G, Rosales-Klintz S, Centis R, D'Ambrosio L, Abubakar I, Bothamley G, Caminero JA, Cirillo DM, Dara M, de Vries G, Aliberti S, Dinh-Xuan AT, Duarte R, Midulla F, Solovic I, Subotic DR, Amicosante M, Correia AM, Cirule A, Gualano G, Kunst H, Palmieri F, Riekstina V, Tiberi S, Verduin R, van der Werf MJ.

Eur Respir J. 2018 May 17;51(5). pii: 1702678. doi: 10.1183/13993003.02678-2017. Print 2018 May.

PMID:
29678945
10.

Low-dose amoxicillin-clavulanate in drug-resistant tuberculosis.

Mishra GP, Caminero JA.

Int J Tuberc Lung Dis. 2018 Apr 1;22(4):465. doi: 10.5588/ijtld.18.0055. No abstract available.

PMID:
29562998
11.

Comments on the SEPAR Guidelines for the Diagnosis and Treatment of Drug-Resistant Tuberculosis.

Caminero JA, Caylá JA, García-García JM, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J.

Arch Bronconeumol. 2018 May;54(5):298. doi: 10.1016/j.arbres.2017.12.015. Epub 2018 Feb 9. English, Spanish. No abstract available.

12.

Bedaquiline: how better to use it.

Caminero JA, Piubello A, Scardigli A, Migliori GB.

Eur Respir J. 2017 Nov 9;50(5). pii: 1701670. doi: 10.1183/13993003.01670-2017. Print 2017 Nov. No abstract available.

13.

Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.

Caminero JA, Piubello A, Scardigli A, Migliori GB.

Eur Respir J. 2017 Jul 5;50(1). pii: 1700648. doi: 10.1183/13993003.00648-2017. Print 2017 Jul. No abstract available.

14.

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.

Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E, Ganatra S, Skrahina A, Akkerman O, Aleksa A, Amale R, Artsukevich J, Bruchfeld J, Caminero JA, Carpena Martinez I, Codecasa L, Dalcolmo M, Denholm J, Douglas P, Duarte R, Esmail A, Fadul M, Filippov A, Davies Forsman L, Gaga M, Garcia-Fuertes JA, García-García JM, Gualano G, Jonsson J, Kunst H, Lau JS, Lazaro Mastrapa B, Teran Troya JL, Manga S, Manika K, González Montaner P, Mullerpattan J, Oelofse S, Ortelli M, Palmero DJ, Palmieri F, Papalia A, Papavasileiou A, Payen MC, Pontali E, Robalo Cordeiro C, Saderi L, Sadutshang TD, Sanukevich T, Solodovnikova V, Spanevello A, Topgyal S, Toscanini F, Tramontana AR, Udwadia ZF, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2017 May 21;49(5). pii: 1700387. doi: 10.1183/13993003.00387-2017. Print 2017 May.

15.

Diagnosis and Treatment of Drug-Resistant Tuberculosis.

Caminero JA, Cayla JA, García-García JM, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J.

Arch Bronconeumol. 2017 Sep;53(9):501-509. doi: 10.1016/j.arbres.2017.02.006. Epub 2017 Mar 27. English, Spanish.

16.

Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.

Dalcolmo M, Gayoso R, Sotgiu G, D'Ambrosio L, Rocha JL, Borga L, Fandinho F, Braga JU, Galesi VM, Barreira D, Sanchez DA, Dockhorn F, Centis R, Caminero JA, Migliori GB.

Eur Respir J. 2017 Mar 22;49(3). pii: 1602445. doi: 10.1183/13993003.02445-2016. Print 2017 Mar.

17.

Tuberculosis drug resistance in Southern Mozambique: results of a population-level survey in the district of Manhiça.

Valencia S, Respeito D, Blanco S, Ribeiro RM, López-Varela E, Sequera VG, Saavedra B, Mambuque E, Morillo MG, Bulo H, Cobelens F, Macete E, Alonso PL, Caminero JA, García-Basteiro AL.

Int J Tuberc Lung Dis. 2017 Apr 1;21(4):446-451. doi: 10.5588/ijtld.16.0694.

PMID:
28284261
18.

The challenge of the new tuberculosis drugs.

Tiberi S, Buchanan R, Caminero JA, Centis R, Arbex MA, Salazar M, Potter J, Migliori GB.

Presse Med. 2017 Mar;46(2 Pt 2):e41-e51. doi: 10.1016/j.lpm.2017.01.016. Epub 2017 Feb 28. Review. French.

PMID:
28256383
19.

In reply.

Bollela VR, Caminero JA.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):124. doi: 10.5588/ijtld.16.0619-2. No abstract available.

PMID:
28157480
20.

Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives.

Rendon A, Tiberi S, Scardigli A, D'Ambrosio L, Centis R, Caminero JA, Migliori GB.

J Thorac Dis. 2016 Oct;8(10):2666-2671. No abstract available.

21.

[Tuberculosis in children. Challenges and opportunities].

Caminero JA, Scardigli A.

An Pediatr (Barc). 2016 Dec;85(6):281-283. doi: 10.1016/j.anpedi.2016.09.012. Epub 2016 Nov 4. Spanish. No abstract available.

22.

Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.

Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Alffenaar JW, Caminero JA, Abdo Arbex M, Alarcon Guizado V, Aleksa A, Dore S, Gaga M, Gualano G, Kunst H, Payen MC, Roby Arias AJ, Skrahina A, Solovic I, Sulis G, Tadolini M, Zumla A, Migliori GB; International Carbapenem Study Group.

Eur Respir J. 2016 Nov;48(5):1503-1507. doi: 10.1183/13993003.01249-2016. Epub 2016 Sep 1. No abstract available.

23.

Factors associated with smoking among tuberculosis patients in Spain.

Jiménez-Fuentes MÁ, Rodrigo T, Altet MN, Jiménez-Ruiz CA, Casals M, Penas A, Mir I, Solano Reina S, Riesco-Miranda JA, Caylá JA; Smoking and Tuberculosis Research Working Group.

BMC Infect Dis. 2016 Sep 14;16:486. doi: 10.1186/s12879-016-1819-1.

24.

Simple and practical measures to reduce tuberculosis transmission in public buildings.

Scardigli A, Caminero JA.

Int J Tuberc Lung Dis. 2016 Sep;20(9):1137-8. doi: 10.5588/ijtld.16.0450. No abstract available.

PMID:
27510232
25.

Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment.

Rodrigo T, Casals M, Caminero JA, García-García JM, Jiménez-Fuentes MA, Medina JF, Millet JP, Ruiz-Manzano J, Caylá J; Working Group of the Integrated Programme of Tuberculosis Research.

PLoS One. 2016 Aug 3;11(8):e0159925. doi: 10.1371/journal.pone.0159925. eCollection 2016.

26.

Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis.

Bollela VR, Namburete EI, Feliciano CS, Macheque D, Harrison LH, Caminero JA.

Int J Tuberc Lung Dis. 2016 Aug;20(8):1099-104. doi: 10.5588/ijtld.15.0864.

27.

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges.

Tadolini M, Garcia-Prats AJ, D'Ambrosio L, Hewison C, Centis R, Schaaf HS, Marais BJ, Ferreira H, Caminero JA, Jonckheere S, Sinha A, Herboczek K, Khaidarkhanova Z, Hayrapetyan A, Khachatryan N, Urtkmelidze Ia, Loreti C, Esposito S, Matteelli A, Furin J, Varaine F, Migliori GB.

Eur Respir J. 2016 Sep;48(3):938-43. doi: 10.1183/13993003.00705-2016. Epub 2016 Jun 23. No abstract available.

28.

Tuberculosis Costs in Spain and Related Factors.

Gullón JA, García-García JM, Villanueva MÁ, Álvarez-Navascues F, Rodrigo T, Casals M, Anibarro L, García-Clemente MM, Jiménez MÁ, Bustamante A, Penas A, Caminero JA, Caylà J; Grupo de Trabajo del Programa Integrado de Investigación en Tuberculosis (PII TB).

Arch Bronconeumol. 2016 Dec;52(12):583-589. doi: 10.1016/j.arbres.2016.05.002. Epub 2016 Jun 17. English, Spanish.

29.

Efficacy and tolerability of ethionamide versus prothionamide: a systematic review.

Scardigli A, Caminero JA, Sotgiu G, Centis R, D'Ambrosio L, Migliori GB.

Eur Respir J. 2016 Sep;48(3):946-52. doi: 10.1183/13993003.00438-2016. Epub 2016 Jun 10. Review. No abstract available.

30.

Nontuberculous mycobacteria in cystic fibrosis patients on the Island of Gran Canaria. A population study.

Campos-Herrero MI, Chamizo FJ, Caminero JA, Gilarranz R, Cabrera G, Cuyás J.

J Infect Chemother. 2016 Aug;22(8):526-31. doi: 10.1016/j.jiac.2016.04.010. Epub 2016 Jun 1.

PMID:
27262751
31.

Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Abdo Arbex M, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Auchynka V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2016 Jun;47(6):1758-66. doi: 10.1183/13993003.00214-2016. Epub 2016 Apr 13.

32.

Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Alarcon Guizado V, Alffenaar JW, Abdo Arbex M, Caminero JA, Centis R, De Lorenzo S, Gaga M, Gualano G, Roby Arias AJ, Scardigli A, Skrahina A, Solovic I, Sulis G, Tadolini M, Akkerman OW, Alarcon Arrascue E, Aleska A, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2016 Apr;47(4):1235-43. doi: 10.1183/13993003.02146-2015. Epub 2016 Mar 10.

33.

The changing landscape in drug resistant-tuberculosis: an analysis of recent advances.

Monedero I, Caminero JA, Bhavaraju R, Sanchez-Montalva A.

Expert Rev Respir Med. 2016 Jun;10(6):603-6. doi: 10.1586/17476348.2016.1164042. Epub 2016 Mar 28. No abstract available.

PMID:
26954921
34.

Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.

Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Arbex MA, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Clin Infect Dis. 2016 May 1;62(9):1188-90. doi: 10.1093/cid/ciw088. Epub 2016 Feb 16. No abstract available.

PMID:
26908794
35.

Classification of antituberculosis drugs: a new proposal based on the most recent evidence.

Caminero JA, Scardigli A.

Eur Respir J. 2015 Oct;46(4):887-93. doi: 10.1183/13993003.00432-2015. No abstract available.

36.

Automated Digital Microscopy in New Tuberculosis Diagnostic Algorithms. Can It Boost Case Finding?

Caminero JA, Migliori GB.

Am J Respir Crit Care Med. 2015 Jun 15;191(12):1352-3. doi: 10.1164/rccm.201504-0790ED. No abstract available.

PMID:
26075421
37.

Resistance to first-line antituberculosis drugs in Spain, 2010-2011. RETUBES Study.

Blanquer R, Rodrigo T, Casals M, Ruiz Manzano J, García-García JM, Calpe JL, Valencia E, Pascual T, Mir I, Jiménez MÁ, Cañas F, Vidal R, Penas A, Caylà JA; Working Group of the Integrated Programme for Research in Tuberculosis in Spain.

Arch Bronconeumol. 2015 Jan;51(1):24-30. doi: 10.1016/j.arbres.2014.06.001. Epub 2014 Jul 11. English, Spanish.

38.

Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rüsch-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM; TBNET.

Eur Respir J. 2014 Jul;44(1):23-63. doi: 10.1183/09031936.00188313. Epub 2014 Mar 23.

39.

Common errors in multidrug-resistant tuberculosis management.

Monedero I, Caminero JA.

Expert Rev Respir Med. 2014 Feb;8(1):15-23. doi: 10.1586/17476348.2014.856758. Epub 2013 Dec 16.

PMID:
24329041
40.

Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence.

Sotgiu G, Centis R, D'Ambrosio L, Spanevello A, Migliori GB; International Group for the study of Linezolid.

Eur Respir J. 2013 Jul;42(1):288-90. doi: 10.1183/09031936.00191712. No abstract available.

41.

Tuberculosis: are we making it incurable?

Caminero JA, Matteelli A, Loddenkemper R.

Eur Respir J. 2013 Jul;42(1):5-8. doi: 10.1183/09031936.00206712. No abstract available.

42.

Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic.

Rodriguez M, Monedero I, Caminero JA, Encarnación M, Dominguez Y, Acosta I, Muñoz E, Camilo E, Martinez-Selmo S, de los Santos S, del Granado M, Casals M, Cayla J, Marcelino B.

Int J Tuberc Lung Dis. 2013 Apr;17(4):520-5. doi: 10.5588/ijtld.12.0481.

PMID:
23485386
43.

Management of multidrug resistant tuberculosis.

Daley CL, Caminero JA.

Semin Respir Crit Care Med. 2013 Feb;34(1):44-59. doi: 10.1055/s-0032-1333546. Epub 2013 Mar 4. Review.

PMID:
23460005
44.

High initial multidrug-resistant tuberculosis rate in Buenaventura, Colombia: a public-private initiative.

Villegas SL, Ferro BE, Perez-Velez CM, Moreira CA, Forero L, Martínez E, Rastogi N, Caminero JA.

Eur Respir J. 2012 Dec;40(6):1569-72. doi: 10.1183/09031936.00018212. No abstract available.

45.

A predictive scoring instrument for tuberculosis lost to follow-up outcome.

Rodrigo T, Caylà JA, Casals M, García-García JM, Caminero JA, Ruiz-Manzano J, Blanquer R, Vidal R, Altet N, Calpe JL, Penas A; Working Group on Completion of Tuberculosis Treatment in Spain.

Respir Res. 2012 Sep 2;13:75. doi: 10.1186/1465-9921-13-75.

46.

Empirical use of fluoroquinolones for chest infections may mask tuberculosis and jeopardise chances of survival.

Leung CC, Caminero JA.

Int J Tuberc Lung Dis. 2012 Sep;16(9):1137. doi: 10.5588/ijtld.12.0518. No abstract available.

PMID:
22871321
47.

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.

Sotgiu G, Centis R, D'Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G, Koh WJ, Schecter GF, Shim TS, Singla R, Skrahina A, Spanevello A, Udwadia ZF, Villar M, Zampogna E, Zellweger JP, Zumla A, Migliori GB.

Eur Respir J. 2012 Dec;40(6):1430-42. doi: 10.1183/09031936.00022912. Epub 2012 Apr 10. Review.

48.

European union standards for tuberculosis care.

Migliori GB, Zellweger JP, Abubakar I, Ibraim E, Caminero JA, De Vries G, D'Ambrosio L, Centis R, Sotgiu G, Menegale O, Kliiman K, Aksamit T, Cirillo DM, Danilovits M, Dara M, Dheda K, Dinh-Xuan AT, Kluge H, Lange C, Leimane V, Loddenkemper R, Nicod LP, Raviglione MC, Spanevello A, Thomsen VØ, Villar M, Wanlin M, Wedzicha JA, Zumla A, Blasi F, Huitric E, Sandgren A, Manissero D.

Eur Respir J. 2012 Apr;39(4):807-19. doi: 10.1183/09031936.00203811.

49.

Rapid test for identification of a highly transmissible Mycobacterium tuberculosis Beijing strain of sub-Saharan origin.

Millán-Lou MI, Alonso H, Gavín P, Hernández-Febles M, Campos-Herrero MI, Copado R, Cañas F, Kremer K, Caminero JA, Martín C, Samper S.

J Clin Microbiol. 2012 Feb;50(2):516-8. doi: 10.1128/JCM.06314-11. Epub 2011 Nov 23.

50.

Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India.

Singla R, Caminero JA, Jaiswal A, Singla N, Gupta S, Bali RK, Behera D.

Eur Respir J. 2012 Apr;39(4):956-62. doi: 10.1183/09031936.00076811. Epub 2011 Sep 29.

Supplemental Content

Loading ...
Support Center